Market Pulse Archives

July 15, 2020, 8:23 a.m. EDT

GW Pharmaceuticals stock slips after Stifel analyst backs off long-standing bullish view

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    GW Pharmaceuticals PLC ADR (GWPH)
  • X
    Cannabis ETF (THCX)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of GW Pharmaceuticals PLC /zigman2/quotes/209686240/composite GWPH +0.36% fell 0.4% in premarket trading, after Stifel Nicolaus analyst Paul Matteis downgraded the maker of the cannabis-derived epilepsy drug Epidiolex, citing disappointing physician feedback regarding "off-label" use of the drug. Matteis cut his rating to hold after being at buy for at least the past two years, and cut his stock price target to $140 from $150. Matteis stressed that the downgrade wasn't a call on GW's second quarter results, which are expected in early August, as he thinks the company will beat expectations as the impact of COVID-19 doesn't seem as bad as projected. "Instead, what's led to a change in our view is conservative physician expectations for Epidiolex use in 'off-label' refractory epilepsy, whereas we believe substantial uptake here is: 1) key to the bull case; and 2) necessary to meet or beat 2021-2025 consensus sales projections," Matteis wrote in a note to clients. The stock has run up 40.3% over the past three months through Tuesday, while the Cannabis ETF /zigman2/quotes/213173823/composite THCX -0.86% has climbed 22.5% and the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.95% has advanced 14.9%.

US : U.S.: Nasdaq
$ 214.94
+0.77 +0.36%
Volume: 2.06M
March 5, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$6.74 billion
Rev. per Employee
US : U.S.: NYSE Arca
$ 18.42
-0.16 -0.86%
Volume: 375,114
March 5, 2021 8:00p
+73.47 +1.95%
Volume: 3.33B
March 5, 2021 5:44p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.